GlobeNewswire

Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study

Share

OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05).

“There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist and we are delighted to see that OB-002O has robust efficacy alone and in combination with an anti-PD-1 antibody in the CT-26 colorectal cancer model. These data support the further preclinical and clinical development of OB-002O for colorectal cancer,” said Dr. Ian McGowan, Chief Scientific Officer for Orion Biotechnology.

Mark Groper, President and CEO of Orion Biotechnology, added, “We are delighted by these preliminary data and look forward to the later stage development of OB-002O in colorectal cancer as well as exploring the efficacy of OB-002O in other cancer models.”

About Orion Biotechnology Canada, Ltd.

Orion Biotechnology Canada Ltd, is a privately held pharmaceutical company founded on the vision of radically improving the health of the global population through successful treatment and prevention of the most serious chronic illnesses and life-threatening diseases. Since 2011, Orion has been developing a robust pipeline of potential products based on novel formulations discovered in different parts of the world. Our close ties to diverse institutions and experts around the globe continue to stimulate the rapid discovery of promising new treatments. With operations in North America, Europe and Asia, Orion brings together innovative technologies from some of the world’s leading research institutions, such as the Mintaka Research Foundation and the Center for Public Health Research at Nanjing University. Learn more at www.orionbiotechnology.com.

Forward-Looking Statements
This press release contains forward-looking information, which reflects Orion’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orion’s control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Ross MacLeod
Orion Biotechnology
Canada Ltd
Phone: +1.343.291.1032
info@orionbiotechnology.com
343 Preston Street
11th Floor, Ottawa, Ontario
www.orionbiotechnology.com
 

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Invitation to Q2 conference call21.8.2019 14:31:00 CESTPress release

Oslo, Norway, 21 August 2019 Vistin Pharma ASA will release its second quarter 2019 results on Thursday 29 August, 2019. Vistin Pharma will host a conference call for all shareholders and interested parties on 29 August at 08:00 CEST. There will be a Q&A session following the management discussion. The second quarter conference call will be available via web and audio through the following access points: Telephone conference: Confirmation Code:........ 9184908 International Dial-In: ..... +44 (0) 2071 928000 Norway, Oslo................. 23960264 United States, New York. 16315107495 Webcast: https://edge.media-server.com/m6/p/cvjpg4fj ***** For further information, please contact: Gunnar Manum CFO +47 95 17 91 90 gunnar.manum@vistin.com

Oboya får en order i Polen21.8.2019 14:29:00 CESTPressemelding

Oboya Horticulture Industries AB (publ) (”Oboya”) har genom sitt helägda dotterbolag VEFI Europa Sp. z o.o i Skierniewice, Polen fått en order på odlingsrännor från befintlig kund i Polen. Ordervärdet uppgår till ca 1,1 MPLN, motsvarande ca 2,7 MSEK. Ordern avser leverans av odlingsrännor till hydroponisk odlingssystem och kommer att levereras löpande under september 2019. Ordervärdet uppgår till 1,1 MPLN, motsvarande ca 2,7 MSEK. Den befintliga kunden F.H. Nowalijka Piotr Wychowałek är ett av de ledande hydroponic odlingsbolag inom sallad och färska örter i Polen. Odlingsrännorna kommer att användas för hydroponisk odling i växthus och odlas utan jord. VEFI grundades 1949 och har varit verksamt i 70 år och är en ledande leverantör av produkter för hydroponisk odlingssystem. Hydroponisk odlingssystem innebär odling i växthus, oberoende av klimat med möjlighet att odla året runt. Odling i hydroponisk odlingssystem sker ofta i ett slutet- och självförsörjande system. Erik Penser Bank AB

Oboya receives an order in Poland21.8.2019 14:29:00 CESTPress release

Oboya Horticulture Industries AB (publ) ("Oboya") has through its wholly owned subsidiary VEFI Europa Sp. z o.o in Skierniewice, Poland received an order for cultivation gutter from an existing customer in Poland. The order value amounted to about PLN 1.1 million, corresponding to about SEK 2.7 million. The order concerns delivery of cultivation gutter to hydroponic cultivation systems and will be delivered continuously during September 2019. The order value amounts to PLN 1.1 million, corresponding to approximately SEK 2.7 million. The existing customer F.H. Nowalijka Piotr Wychowałek is one of the leading hydroponic growing companies in lettuce and fresh herbs in Poland. The cultivation gutter will be used for hydroponic cultivation in greenhouses and grown without soil. VEFI was founded in 1949 and has been operating for 70 years and is a leading supplier of products for hydroponic cultivation systems. Hydroponic cultivation system means cultivation in greenhouses, regardless of cli

Conference call 28 August at 10.00 (CEST) about Interim Report Q2 201921.8.2019 13:07:00 CESTPress release

21/08/2019 COMPANY ANNOUNCEMENT 11/2019 Goodvalley will release its Interim Report Q2 2019 on 27 August 2019. On 28 August 2019 at 10.00 (CEST), Goodvalley will host a conference call at which CEO Hans Henrik Pedersen and Vice CEO Kristian Brokop will provide comments on financial and operational performance in Q2 2019, the outlook and answer questions. Registration is not required. The conference call will be conducted in English and can be followed live here: https://edge.media-server.com/mmc/p/vuzfpixi Participants should dial the numbers provided below and state conference code Denmark: +45 32 72 80 42 Norway: +47 239 60264 Sweden: +46 (0)850 692180 Poland +48 222 120 152 United Kingdom: +44 (0)844 571 8892 United States: +1 631 5107495 Further Information Group Communications, Anne Axelgaard + 45 76 52 20 00 investor@goodvalley.com Goodvalley at a glance Goodvalley is an international producer of high quality pork products operating in Poland, Ukraine and Russia based on Danish pr

Rovio Entertainment Corp.: Vodafone and Hatch launch the first premium cloud gaming service in Germany21.8.2019 13:00:00 CESTPress release

Rovio Entertainment Corporation Press Release August 21, 2019 Vodafone and Hatch launch the first premium cloud gaming service in Germany Hatch’s mobile games streaming service now available for Vodafone 5G customers across Germany Available on Android 5G devices, Hatch is optimized for gaming as part of Vodafone’s 5G roll-out Hatch offers Vodafone 5G customers complimentary access to Hatch Premium, which includes unlimited access to more than 100 premium games Vodafone and Hatch, Rovio Entertainment Corp. subsidiary, today announced the launch of the first 5G-optimised cloud gaming service in Germany. Introduced as part of Vodafone Germany’s 5G switch-on, avid and casual gamers alike will be able to stream games instantly from their Android 5G-enabled devices. The Hatch app is now available to download from the Google Play Store. Vodafone 5G customers will have 3-months of complimentary access to Hatch Premium, Hatch’s subscription level plan. After this period, the service will cost

Delårsrapport januari - juni 201921.8.2019 12:10:00 CESTPressemelding

ELECTRA GRUPPEN AB (publ) orgnr. 556065-4054 DELÅRSRAPPORT JANUARI – JUNI 2019 Stärkta marginaler ger positiv resultatutveckling Retailsegmentet uppvisar stärkta marginaler vilket påverkar resultatet positivt Integrationen av Em Home belastar enligt plan koncernresultatet med ca 1,8 MSEK första halvåret Samarbetet med Elon inlett, framskrider enligt plan APRIL – JUNI 2019 Nettoomsättningen uppgick till 414,0 (442,1) MSEK. Rörelseresultatet uppgick till 3,0 (2,2) MSEK. Resultat efter skatt uppgick till 2,2 (1,5) MSEK. Resultat per aktie uppgick till 0,41 (0,29) SEK. Kassaflödet från den löpande verksamheten uppgick till -38,3 (-7,7) MSEK. Eget kapital per aktie uppgick till 36,22 (36,05) SEK. JANUARI – JUNI 2019 Nettoomsättningen uppgick till 802,1 (842,6) MSEK. Rörelseresultatet uppgick till 4,8 (4,4) MSEK. Resultat efter skatt uppgick till 3,8 (3,4) MSEK. Resultat per aktie uppgick till 0,72 (0,66) SEK. Kassaflödet från den löpande verksamheten uppgick till -6,6 (13,2) MSEK. Eget kapi